Physician profile
Donald R Sutherland
NPI 1497749725
$4,738.33
in general payments reported to CMS, 2019-2025
22 companies · $43.49 in 2025
The $43.49 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,454 · 2020: $711 · 2021: $46.65 · 2022: $629 · 2023: $904 · 2024: $951 · 2025: $43.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,551.42 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $774.57 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $549.62 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $527.00 | 2019-2024 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $267.00 | 2019-2024 | |
| Gilead Sciences, INC. | $200.14 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $111.81 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $109.37 | 2022 | |
| Ardelyx, INC. | $86.45 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $82.35 | 2023-2024 | Dupixent |
| Ucb, INC. | $73.95 | 2019 | |
| Genzyme Corporation | $63.96 | 2023 | |
| Ironwood Pharmaceuticals, INC | $50.60 | 2020-2023 | Linzess |
| Merck Sharp & Dohme LLC | $46.96 | 2019-2020 | |
| Shire North American Group INC | $44.05 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $41.47 | 2022 | |
| Shionogi INC | $40.68 | 2019 | |
| Celgene Corporation | $34.16 | 2022 | |
| Intercept Pharmaceuticals, INC. | $28.51 | 2020 | |
| Endo Pharmaceuticals INC. | $27.12 | 2019 | |
| Romark Laboratories, Lc | $14.34 | 2019 | |
| Allergan, INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.